$GENB News

Generate Biomedicines to Participate in November Investor Conferences

Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration

'Zealand Pharma Makes Deal With Generate Worth Up to $1.2 Billion' - Bloomberg

Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm

HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Roswell Park And Generate Biomedicines Announce First Patient Dosed In First-In-Human Clinical Trial Evaluating GB-5267, Investigational, Autologous IL-18 Armored CAR T-Cell Therapy

Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

Generate Biomedicines Inc. to Participate in September Investor Conferences

HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30

EXCLUSIVE: Nvidia GPUs Are Essential—But They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says

Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate

Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted

Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)

A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer